Gadoxetic acid-enhanced MRI in the detection of recurrent hepatocellular carcinoma in a patient with synchronous malignant tumors
https://doi.org/10.24835/1607-0763-2019-4-50-56
Abstract
The purpose of this case report is to present a value of gadoxetic acid¬enhanced MRI in the detection of an early recurrent hepatocellular carcinoma in a patient with synchronous multiple malignant tumors. The specific indications of using liver-specific contrast agents were introduced.
About the Authors
A. B. LukianchenkoRussian Federation
Dr. of Sci. (Med.), Professor, leading researcher of the diagnostic radiology department
B. M. Medvedeva
Russian Federation
Dr. of Sci. (Med.), leading researcher of the diagnostic radiology department
K. A. Romanova
Russian Federation
Cand. of Sci. (Med.), researcher of the diagnostic radiology department
23, Kashirskoe shosse, Moscow, 115478
Phone: +7-926-079-20-00
G. G. Karmazanovsky
Russian Federation
сorresponding member of the Russiаn Асаdemy of Sсienсes, Dr. of Sci. (Med.), Professor, Heаd of the Diagnostic Rаdiologydepаrtment; Professor of radiology department
References
1. Lukiyanchenko A.B., Medvedeva B.M. Current approaches to distinguishing liver tumors. Moscow: Practical medicine, 2015. 115 p. (In Russian)
2. Lukiyanchenko A.B., Medvedeva B.M., Shabanov M.A., Breder V.V., Lukiyanchenko K.A. Current approaches to diagnosis and treatment of hepatocellular carcinoma. Medical visualization. 2013; 4: 36–53. (In Russian)
3. Medvedeva B.M., Romanova K.A. Effective diagnostic algorithm as the key to correct tumor staging and treatment response assessment. Malignant tumors. 2016; 4 (21): 125–127. (In Russian)
4. Medvedeva B.M., Lukiyanchenko A.B. MR imaging in diagnosis of hepatocellular carcinoma. Pharmateca. 2012; S1: 23–25. (In Russian)
5. Lomovtseva K.H., Karmazanovsky G.G. Role of MRI with hepatospecific contrast agent. Clinical medicine. 2018; 6 (3): 213–221. (In Russian)
6. Ringe K.I., Husarik D.B., Sirlin C.B., Merkle E.M. Gadoxetate Disodium-Enhanced MRI of the Liver: Part I. Protocol Optimization and Lesion Appearance in the Noncirrhotic Liver. Am. J. Roentgenol. 2010; 195:13–28. https://doi.org/ 10.2214/AJR.10.4392.
7. Cruite I., Schroeder M., Merkle E.M., Sirlin C.B. Gadoxetate Disodium-Enhanced MRI of the Liver: Part 2. Protocol Optimization and Lesion Appearance in the Cirrhotic Liver. Am. J. Roentgenol. 2010; 195: 29–41. https://doi.org/10.2214/ajr.10.4538.
8. Yagudina R.I., Kulikov А.Yu., Zinchuk I.Yu., Kotlyarov P.М., Sergeev N.I., Andrianov М.М., Gvozdev А.А., Solodky V.A. Pharmacoeconomic Study of Liver Lesions Diagnostics by Different Contrast Media. Medical visualization. 2010; 3: 118–128. (In Russian)
9. Zech C.J., Grazioli L., Jonas E., Ekman M., Niebecker R., Gschwend S., Breuer J., Jonsson L., Kienbaum S. Healtheconomic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden. Eur. Radiol. 2009; 19 (Suppl. 3): S753–
10. https://doi.org/10.1007/s00330-009-1432-4.
11. Zech C.J., Herrman K.A., Reiser M.F., Schoenberg S.O. MR Imaging in patients with suspected liver metastasis: value of liver-specific contrast agent Gd-EOB-DTPA. Magn. Reson. Med. Sci. 2007; 6: 43–52. https://doi.org/10.2463/mrms.6.43.
12. Medvedeva B.M. Nosological strategy of liver tumors imaging. Doctoral thesis. Moscow, 2015. 48 p. (In Russian)
13. Dolgushin B.I., Tyurin I.E., Lukyanchenko A.B., Medvedeva B.M., Dronova E.L., Schima W., Ringl H. standards of CT and MRIprocedures using intravenous contrast enhance ment in oncology. Medical alphabet. 2013; 3 (23): 29–37. (In Russian)
Review
For citations:
Lukianchenko A.B., Medvedeva B.M., Romanova K.A., Karmazanovsky G.G. Gadoxetic acid-enhanced MRI in the detection of recurrent hepatocellular carcinoma in a patient with synchronous malignant tumors. Medical Visualization. 2019;(4):50-56. (In Russ.) https://doi.org/10.24835/1607-0763-2019-4-50-56